News
ABBV
159.62
-4.58%
-7.67
AbbVie (NYSE:ABBV) Sinks as Humira Drug Sees Increased Competition
TipRanks · 5h ago
AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q
Shares of AbbVie lost 4.6% to close at $159.62 on Friday. The company warned about the effects of losing the exclusivity of its Humira patent. The drugmaker guided for second-quarter revenue of $14 billion. Humira is the highest-grossing drug ever.
Dow Jones · 7h ago
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
AbbVie shares closed down 4.6% on Friday. The company's first-quarter sales and earnings results topped estimates. But sales of Humira are declining at a slower pace than expected. The pharmaceutical company's stock is already priced for the decline in Humira.
The Motley Fool · 7h ago
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
AbbVie's (ABBV) first quarter 2024 earnings conference call will be held today. Rick Gonzalez, chairman of the board and chief executive officer, will discuss the company's results. The company will also discuss its strategy for the period ending March 31, 2024. Today's call is being recorded.
The Motley Fool · 8h ago
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Evernorth Health Services will make a Humira biosimilar available to patients with no out-of-pocket costs. Humira is AbbVie Inc’s blockbuster arthritis drug. The biosimilar price is about 85% lower than that of branded Humira. The company is a subsidiary of The Cigna Group.
Benzinga · 8h ago
AbbVie stock slides 6% amid concerns about falling Humira sales
AbbVie stock slides 6% amid concerns about falling Humira sales. Cigna plans to offer a biosimilar of the drug's top-selling drug Humira at no cost to certain patients. Humira global sales tumbled 36% year-over-year to $2.27B.
Seeking Alpha · 9h ago
BUZZ-U.S. STOCKS ON THE MOVE-Chevron, Intel, Alphabet
Dow Jones Industrial Average was up 0.65% on Friday. Alphabet pushed its market value over $2 trillion. Top three S&P 500 percentage losers: Chevron, Intel, Alphabet and Exxon Mobil. The Nasdaq Composite was up 2.31%. Wall Street's main indexes advanced after robust quarterly results.
Reuters · 9h ago
More than half of the S&P 500 names that reported results this week beat top and bottom line - Earnings Scorecard
More than half of the S&P 500 names that reported results this week beat top and bottom line. Of the 156 companies that reported, 125 had EPS above analyst expectations, 28 missed consensus, and three were in line. This week was one of the heaviest in terms of companies reporting their first quarter earnings.
Seeking Alpha · 9h ago
Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?
The S&P 500 gained over 1% on Friday and is up 2.8% this week. The Nasdaq 100 is on track for its best week in seven months. Strong earnings reports from Alphabet and Microsoft restored positive sentiment in the market. The Magnificent Seven gained a combined $400 billion in a day.
Benzinga · 9h ago
Interesting ABBV Put And Call Options For July 19th
NASDAQ · 11h ago
BUZZ-U.S. STOCKS ON THE MOVE-HCA Healthcare, ResMed, LyondellBasell
Dow Jones Industrial Average was up 0.24% on Friday. Alphabet pushed its market value over $2 trillion. Most growth stocks rose after robust quarterly results from Alphabet. HCA Healthcare, ResMed, LyondellBasell were among the top stocks on the NYSE.
Reuters · 11h ago
AbbVie's Q1: Positive Surprise
Seeking Alpha · 11h ago
ABBV.US (ABBV.US) “New Momentum” is gaining momentum! 2024 EPS forecast raised
Zhitongcaijing · 12h ago
AbbVie Q1 report beats Street despite plunging Humira sales
Seeking Alpha · 12h ago
AbbVie off 3% despite quarterly beats, 2024 guidance raise
AbbVie's shares are down 3% despite quarterly beats, 2024 guidance raise. Skyrizi and Rinvoq sales helped make up for decline in Humira sales in the quarter. The company also raised its adjusted diluted EPS guidance for the year to $11.33.
Seeking Alpha · 13h ago
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
NASDAQ · 13h ago
AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say
NASDAQ · 13h ago
ABBVIE INC - EXEC SAYS EXPECT U.S. HUMIRA EROSION OF 32%, REFLECTING A STEP-UP IN VOLUME EROSION AND WITH THE RECENT CVS FORMULARY CHANGE
Reuters · 13h ago
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
AbbVie reports first-quarter adjusted EPS of $2.31, down 6.1% Y/Y. The company beat the consensus estimate. First-quarter net revenues reached $12.31 billion, up 0.7%. The immunology portfolio generated $5.37 billion in sales.
Benzinga · 13h ago
ABBVIE SHARES REVERSE COURSE FROM PREMARKET, LAST DOWN 1.7%
Reuters · 13h ago
More
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.